(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
13 August 2020 (13.08.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/163365 A2

(51) International Patent Classification:
C12N 15/11 (2006.01)

(21) International Application Number:
PCT/US2020/016623

(22) International Filing Date:
04 February 2020 (04.02.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/800,999 04 February 2019 (04.02.2019) US
62/818,677 14 March 2019 (14.03.2019) US

(71) Applicant: **KSQ THERAPEUTICS, INC.** [US/US]; 610 Main Street North, 4th Floor, Cambridge, Massachusetts 02139 (US).


(72) Inventors: **BENSON, Micah**; c/o: KSQ THERAPEUTICS, INC., 610 Main Street North, 4th Floor, Cambridge, Massachusetts 02139 (US). **SCHLABACH, Michael**; c/o: KSQ THERAPEUTICS, INC., 610 Main Street North, 4th Floor, Cambridge, Massachusetts 02139 (US). **KRYUKOV, Gregory**; c/o: KSQ THERAPEUTICS, INC., 610 Main Street North, 4th Floor, Cambridge, Massachusetts 02139 (US). **CADZOW, Anne Louise**; c/o: KSQ THERAPEUTICS, INC., 610 Main Street North, 4th Floor, Cambridge, Massachusetts 02139 (US). **FLEUR LE MERCIER, Isabelle**; c/o: KSQ THERAPEUTICS, INC., 610 Main Street North, 4th Floor, Cambridge, Massachusetts 02139 (US). **STEGMEIER, Frank**; c/o: KSQ THERAPEUTICS, INC., 610 Main Street North, 4th Floor, Cambridge, Massachusetts 02139 (US).

(74) Agent: **WILKINS, Andrew**; Lathrop GPM LLP, 28 State Street, Boston, Massachusetts 02109 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: COMBINATION GENE TARGETS FOR IMPROVED IMMUNOTHERAPY

Fig. 1



(57) Abstract: The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.

WO 2020/163365 A2

[Continued on next page]

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

— *with sequence listing part of description (Rule 5.2(a))*